Arcturus Therapeutics (NASDAQ:ARCT) Stock Price Expected to Rise, Citigroup Analyst Says

Arcturus Therapeutics (NASDAQ:ARCT) had its price target boosted by equities researchers at Citigroup from $7.00 to $8.00 in a report issued on Wednesday,Benzinga reports. The firm presently has a “neutral” rating on the biotechnology company’s stock. Citigroup’s price target suggests a potential upside of 10.34% from the company’s current price.

A number of other brokerages have also weighed in on ARCT. Weiss Ratings restated a “sell (d-)” rating on shares of Arcturus Therapeutics in a report on Wednesday, January 21st. Wall Street Zen lowered Arcturus Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, December 13th. HC Wainwright lowered their price objective on Arcturus Therapeutics from $12.00 to $9.00 and set a “neutral” rating for the company in a research report on Tuesday, November 11th. Piper Sandler cut their target price on Arcturus Therapeutics from $72.00 to $25.00 and set an “overweight” rating on the stock in a research report on Wednesday. Finally, Roth Mkm started coverage on shares of Arcturus Therapeutics in a report on Thursday, January 22nd. They set a “buy” rating and a $20.00 price objective on the stock. Nine investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $30.33.

Arcturus Therapeutics Price Performance

Shares of NASDAQ ARCT opened at $7.25 on Wednesday. The company has a market cap of $206.05 million, a price-to-earnings ratio of -3.05 and a beta of 2.40. The stock’s 50-day moving average is $7.30 and its two-hundred day moving average is $11.32. Arcturus Therapeutics has a 1-year low of $5.85 and a 1-year high of $24.17.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings data on Tuesday, March 3rd. The biotechnology company reported ($1.03) EPS for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.11). The company had revenue of $7.20 million for the quarter, compared to analyst estimates of $14.32 million. Arcturus Therapeutics had a negative return on equity of 29.13% and a negative net margin of 80.19%. Equities research analysts anticipate that Arcturus Therapeutics will post -2.22 earnings per share for the current fiscal year.

Institutional Trading of Arcturus Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. ARK Investment Management LLC increased its position in Arcturus Therapeutics by 39.4% during the 4th quarter. ARK Investment Management LLC now owns 2,611,099 shares of the biotechnology company’s stock worth $16,006,000 after purchasing an additional 738,378 shares during the period. Sumitomo Mitsui Trust Group Inc. boosted its stake in shares of Arcturus Therapeutics by 4.0% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,026,588 shares of the biotechnology company’s stock worth $12,423,000 after acquiring an additional 78,753 shares in the last quarter. Amova Asset Management Americas Inc. boosted its stake in shares of Arcturus Therapeutics by 4.0% during the 4th quarter. Amova Asset Management Americas Inc. now owns 2,026,588 shares of the biotechnology company’s stock worth $12,403,000 after acquiring an additional 78,753 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Arcturus Therapeutics by 4.2% in the 3rd quarter. Vanguard Group Inc. now owns 1,885,605 shares of the biotechnology company’s stock worth $34,752,000 after acquiring an additional 75,440 shares during the period. Finally, Bank of America Corp DE increased its stake in Arcturus Therapeutics by 112.0% in the 3rd quarter. Bank of America Corp DE now owns 620,055 shares of the biotechnology company’s stock valued at $11,428,000 after purchasing an additional 327,626 shares in the last quarter. Hedge funds and other institutional investors own 94.54% of the company’s stock.

Key Headlines Impacting Arcturus Therapeutics

Here are the key news stories impacting Arcturus Therapeutics this week:

• Positive Sentiment: Company reiterated clinical progress: Arcturus outlined launch of a 12‑week Phase II cystic fibrosis (CF) trial and said it expects regulatory clarity for ARCT‑810 in 2026, which supports longer‑term pipeline value. Arcturus outlines 12-week Phase II CF trial launch and expects regulatory clarity for ARCT-810 in 2026
• Positive Sentiment: Major sell‑side firms still carry sizable upside even after cuts — Piper Sandler kept an overweight rating and, despite lowering its target, the revised target implies significant upside versus the current price. This signals continued analyst conviction in the stock’s longer‑term recovery. Piper Sandler price target update (Benzinga)
• Neutral Sentiment: Arcturus will present at the Leerink Partners 2026 Global Healthcare Conference (fireside chat on March 11), which gives management a platform to update investors on trials and regulatory timing. Arcturus Therapeutics to Attend Upcoming Investor Conference
• Neutral Sentiment: Short‑interest data in recent reports appear inconsistent/zeroed out (shows 0 shares and NaN increases), so there’s no reliable signal from short interest yet. Investors should treat those figures with caution.
• Negative Sentiment: Q4 results disappointed: EPS and revenue missed analysts’ expectations (revenue roughly $7.2M vs. ~$14.3M consensus) and margins remained negative — this is the primary near‑term catalyst pushing the stock lower. Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline Progress
• Negative Sentiment: Market reaction and coverage changes: Several firms cut price targets substantially (examples include Citigroup and Piper Sandler reducing multi‑year targets), which increases near‑term downward pressure despite some retained buy/overweight ratings. Citigroup lowers price target on Arcturus (Tickerreport)

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.